



News Release

Not intended for media outside the U.S. or Canada

February 06, 2026

EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities

- **EMD Serono’s complete fertility medication portfolio, including Gonal-f®, the most-prescribed follicle-stimulating hormone in the U.S., is now accessible via TrumpRx.gov and FertilityInstantSavings.com**
- **New patient access pathways reinforce EMD Serono’s mission to support people facing infertility and align with the Executive Order “Expanding Access to In Vitro Fertilization.”**

BOSTON, Mass., February 06, 2026 - EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, in collaboration with President Trump’s administration, announced new patient access pathways to make its complete portfolio of infertility medications used for in vitro fertilization (IVF), including Gonal-f® (follitropin alfa for injection), Ovidrel® (choriogonadotropin alfa injection), and Cetrotide® (cetorelix acetate for injection), more accessible to prescribed infertility patients in the United States.

Prescribed patients can now access a single coupon covering EMD Serono’s entire fertility medication portfolio on TrumpRx.gov. Product coupons and information on how to utilize the coupon with participating pharmacy partners are available through either TrumpRx.gov or EMD Serono’s new [Fertility Instant Savings website](https://FertilityInstantSavings.com). The Fertility Instant Savings platform provides FAQs, additional resources, and can be accessed directly or via a link on the TrumpRx website. TrumpRx.gov and our Fertility Instant Savings website will offer a simplified process for Americans pursuing medically assisted reproduction who have been



prescribed one of our fertility products and are paying for their infertility medications out-of-pocket.

"Behind every fertility treatment is a person's hope and dream. Each step and effort towards easing this burdensome journey makes a real impact for these patients," said Miguel Fernández Alcalde, President of EMD Serono. "We care deeply about every patient we serve, and these new pathways to access our therapies reflect our belief that breakthrough science must reach the people who need it most."

In the United States, more than 10 million women struggle to have a baby. For many, accessing fertility treatments has been a significant barrier to starting or expanding their families. The collaboration with the Trump Administration makes it possible for the company to advance its long-standing commitment to expand access to the innovations within its fertility medication portfolio and the goals outlined in the Executive Order, "Expanding Access to In Vitro Fertilization."

To further expand therapeutic options for patients with complex fertility issues in the U.S., EMD Serono received the FDA's Commissioner's National Priority Voucher (CNPV) for one of its fertility products that is available in many countries outside of the U.S., known as Pergoveris® (follitropin alfa/lutropin alfa), a potential therapeutic option for follicular development in women undergoing ovarian stimulation and who are candidates for concurrent therapy with FSH (follicle stimulating hormone) and LH (luteinizing hormone). This voucher is one of the first nine products selected under this initiative, designed to expedite drug review processes for products that align with critical national health priorities in the U.S.

The company's science was instrumental in the birth of the first-ever IVF baby in the U.S. and today has supported over 6 million successful births worldwide through its therapeutic innovations, devices, and access services to help families achieve the dream of having a child.

For more information, contact our **Media Relations** team.



Email: mediarelations@emdserono.com

About EMD Serono, Inc.

EMD Serono - the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada - aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono's global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts.

www.emdserono.com.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.